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Purpose: EGFR amplification and mutation (i.e., EGFRvIII) are found in 40% of primary
GBM tumors and are believed to contribute to tumor development and therapeutic
resistance. This study was designed to investigate how EGFR mutational status mod-
ulates response to multimodality treatment with cetuximab, an anti-EGFR inhibitor, the
chemotherapeutic agent, temozolomide (TMZ), and radiation therapy (RT).
Methods andMaterials: In vitro and in vivo experiments were performed on two isogenic
U87 GBM cell lines: one overexpressing wildtype EGFR (U87wtEGFR) and the other over-
expressing EGFRvIII (U87EGFRvIII).
Results: Xenografts harboring EGFRvIII were more sensitive to TMZ alone and TMZ in
combination with RT and/or cetuximab than xenografts expressing wtEGFR. In vitro exper-
iments demonstrated that U87EGFRvIII-expressing tumors appear to harbor defective DNA
homologous recombination repair in the form of Rad51 processing.
Conclusion: The difference in sensitivity between EGFR-expressing and EGFRvIII-
expressing tumors to combined modality treatment may help in the future tailoring of
GBM therapy to subsets of patients expressing more or less of the EGFR mutant.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and aggres-
sive primary adult brain tumor. The standard of care is maximal
surgical resection followed by radiation therapy (RT) combined
with concurrent and adjuvant temozolomide (TMZ), producing a
median survival of only 14.6 months (Stupp et al., 2007).
Molecular targeted agents against key growth factors and sig-
naling pathways in GBM are currently being investigated. In
particular, the epidermal growth factor receptor (EGFR) appears
to play an important role in tumor growth, survival, and thera-
peutic resistance (Chakravarti et al., 2002). Amplification of the
EGFR gene, resulting in overexpression of EGFR protein (Fred-
erick et al., 2000) is seen in 30–50% of GBM cases. Additionally,
EGFR proteins are often mutated in GBM. The most common
variant, EGFRvIII, has a truncated extracellular domain imparting
ligand-independent constitutive activity (Wong et al., 1992).
Erbitux™(cetuximab) is an anti-EGFR chimeric mouse-human
monoclonal antibody approved by The U.S. Food and Drug
Administration for colon and head-and-neck cancer. Cetuximab
can bind to EGFRvIII as well as EGFR through domain III in
the extracellular portion of the receptor, thereby inhibiting down-
stream signaling pathways (Patel et al., 2007). Unfortunately,
clinical trials of cetuximab in GBM have produced overall dis-
appointing results (Neyns et al., 2009). We hypothesized that
EGFR mutational status modulates the response to cetuximab,
when combined with radiation and temozolomide in the treat-
ment of GBM. In vitro and in vivo experiments were performed
on two isogenic U87 GBM cell lines: over expressing either wild-
type (U87wtEGFR) or mutant (U87EGFRvIII) EGFR receptor to
test this hypothesis.
MATERIALS AND METHODS
IMMUNOBLOT
Western blotting was performed as previously described (Wachs-
berger et al., 2012). Primary antibodies against EGFR, EGFRvIII,
and O-6-methylguanine-DNA methyltransferase (MGMT) were
obtained from Cell Signaling Technologies (Beverly, MA, USA).
ANIMAL AND TUMOR MODEL
U87 GBM cells (American Type Culture Collection), originally
lacking expression of EGFR were stably transfected with EGFR or
EGFRvIII as previously described (Wang et al., 2006; Figure 1A).
Cell suspensions (5× 105 cells in 100µL phosphate buffered
saline) were implanted subcutaneously (SC) into the right hind
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FIGURE 1 | Characterization of cell lines and dosing schedule. (A)
Immunoblot of U87 cells expressing wild type (wt) EGFR or EGFRvIII. (B)
Immunoblot of MGMT status of U87 transfectants: (a)=LN18 glioma;
(b)=MGMT positive control; (c)=U87wtEGFR; (d)=U87EGFRvIII; (e)=U87
parent. (C) Dosing schedule. Mice were randomized into eight experimental
groups (10–15 animals per group).
limbs of athymic NCR NUM mice (Taconic Farms, Hudson, NY,
USA). Tumors were synchronized to be approximately 60 mm3
at the start of treatment (day 0) and were measured 3–4 times
per week, for up to 6 weeks of follow-up, or until they reached
2,000 mm3 (in accordance with IACUC regulations). All animals
were randomized among treatment groups. Tumor size was deter-
mined by direct measurement with calipers and calculated by the
formula: (smallest diameter2×widest diameter)/2.
DRUG AND RADIATION TREATMENT
Cetuximab (supplied by Imclone Pharmaceuticals) was admin-
istered i.p. at 12 mg/kg three times a week for 2 weeks, starting
on Day 0. TMZ (obtained through Thomas Jefferson University
pharmacy) was administered by oral gavage at 15 mg/kg daily on
Days 0–4. Irradiation was performed on anesthetized mice using
X-rays generated by a PanTak, 310 kVe X-ray machine, 0.25 mm
Cu+ 1 mm Al added filtration, at 125 cGy per min. Dosimetry
was performed by an in-the-beam ionization chamber calibrated
against a primary standard. Corrections were made daily for
humidity, temperature, and barometric pressure. Mice were anes-
thetized with a combination of ketamine and acepromazine at a
concentration of 37.5 and 0.2 mg/kg, respectively, to provide 25–
30 min of sedation. Each mouse was confined in a lead casing with
its tumor-bearing leg extended through an opening on the side to
allow the tumor to be irradiated locally. Radiation was adminis-
tered as three daily fractions of 5 Gy each on days 0, 1, and 2. On
days when radiation was administered with cetuximab and temo-
zolomide, drugs were given 2 h before radiation. Dosing schedule
is shown in Figure 1C.
STATISTICAL ANALYSIS OF TUMOR GROWTH CURVES
Curves were analyzed via mixed-effects regression, as previously
described (Wachsberger et al., 2011). Briefly, this approach fits a
random growth curve to each animal’s data and then statistically
“averages” these curves within each treatment group to estimate
an overall effect for each group. This approach does not depend
on an arbitrary endpoint target tumor size, yields generalizable
parameters of interest (e.g., average daily tumor growth rate and
tumor doubling time), and can investigate treatment interactions.
It is also quite powerful since it utilizes the repeated tumor size
measurements obtained over the entire study period, while it
appropriate handles unbalanced data (i.e., different number of
measurements per animal) and the correlation of each animal’s
measurements over time. All statistical analyses were conducted in
SAS 9.2 (SAS Institute Inc., Cary, NC, USA, 1999–2001).
CELL VIABILITY ASSAY
Cell viability was measured by an MTS assay (Promega, Madi-
son, WI, USA). Exponentially growing cells were plated at 5000
cells/well in a 96-well plate and allowed to incubate for 24 h before
treatment with increasing doses of TMZ and the RAD51 inhibitor,
B02 (5µM; Sigma Aldrich, St. Louis, MO, USA) as described in
Results. Cells were assayed 24 h following treatment.
CLONOGENIC CELL SURVIVAL AFTER RADIATION, CETUXIMAB, AND/OR
TMZ
Clonogenic cell survival assays was performed with exponentially
growing cells in the absence or presence of cetuximab (10µg/ml)
and/or TMZ (10µM), as follows: cells were plated in T-25 flasks
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and were irradiated with increasing doses of X-rays with a PanTak
310 keV X-ray machine at 0.25 mm Cu plus 1 mm Al added filtra-
tion, at 125 cGy/min. Following irradiation, drugs were removed
and flasks were incubated at 37˚C for 2 weeks, after which cultures
were stained and scored for colony formation. Only colonies of 50
or more cells were counted. Three replicates per dose were studied.
Survival curves were generated after normalizing for cell killing by
individual drugs alone or in combination. The surviving fraction
value was corrected for cellular multiplicity to provide single-cell
survival (Sinclair and Morton, 1965). Data were fit to a linear qua-
dratic model for cell survival using GraphPad Prism software (La
Jolla, CA, USA). The mean± SEM from at least three independent
experiments were obtained.
ANALYSIS OF Rad51 FOCI
Cells were fixed 30 min, 4, 6, 24, and 48 h following treatment with
4 Gy X-rays with and without prior incubation (24 h) with TMZ
(5µM). Primary mouse monoclonal anti-Rad51 (Abcam, Cam-
bridge, MA, USA) was added at a dilution of 1:500 in 5% bovine
serum albumin (BSA). After incubation and washing, secondary
donkey anti-goat (Alexa Fluor 594, Invitrogen, Molecular Probes,
Eugene, OR, USA) was added at a 1:500 dilution in 5% BSA-PBS.
Rad51 foci were visualized). . . on a Zeiss LSM 510 Meta Confocal
Microscope (Carl Zeiss Microscope Inc., Thornwood, NY, USA)
using a 40X oil immersion lens and analyzed by Image J soft-
ware provided by NIH. Cells containing nuclei with three or more
Rad51 foci were classified as positive for DNA damage. Fifty nuclei
were counted for each treatment. Experiments were repeated in
triplicate. The Akt inhibitor, BAY 1001931 was provided by Bayer
Pharma AG.
RESULTS
IN VIVO STUDIES
Tolerability and modeling
All treatments were well tolerated in the animals with no observ-
able loss of body weight. For U87wtEGFR-expressing tumor exper-
iments, a linear tumor growth model (on the log-10 scale) fit the
data quite well, with the exception of the three-way combination
group, for which a quadratic term was necessary (Figure 2A). For
the U87EGFRvIII expressers, in five out of the eight groups (TMZ
alone, and all combination treatment groups), a linear tumor
growth model was not appropriate because of tumor regression
in many animals. Therefore, quadratic terms were necessary for
these groups (Figure 2B).
Effect of radiation, TMZ, and cetuximab on U87wtEGFR tumor
xenograft growth
Table 1 summarizes the geometric mean tumor volume (in mm3)
over time, as well as the tumor growth rate and doubling time, for
each treatment group. The control group had an estimated average
daily tumor growth rate of 24%, corresponding to an estimated
average tumor doubling time of about 3.2 days. Treatment with
radiation alone significantly slowed tumor growth compared to
the untreated control group (p= 0.002), while TMZ alone and
cetuximab alone were both marginally better than the controls
(p= 0.077 and 0.098, respectively).
The two-way combination groups (radiation plus TMZ, radi-
ation plus cetuximab, and TMZ plus cetuximab) had estimated
average tumor growth rates between 8 and 13% and were all
significantly better than the control group (all p-values< 0.001).
Radiation combined with TMZ did not show benefit over the cor-
responding single treatments (p= 0.756 against radiation alone
and 0.159 against TMZ alone). Radiation plus cetuximab did
not show benefit over radiation alone (p= 0.383), but was better
than cetuximab alone (p= 0.038). Finally, TMZ plus cetuximab
was significantly better than either radiation alone (p= 0.004) or
cetuximab alone (p= 0.002).
The three-way treatment combination group showed a
markedly different tumor growth pattern, with tumors being
stable or growing somewhat during the first week and shrink-
ing afterward. The average rate of shrinkage accelerated over
time (see Table 1). In 5 out of 12 animals in this group (42%),
tumors regressed completely within 4 weeks of treatment initia-
tion. The three-way combination group also seemed better than
the cetuximab-only group (p= 0.095) and the TMZ plus cetux-
imab group (p= 0.077), which had only one tumor regression
each.
Effect of RT, TMZ, and cetuximab on U87EGFRvIII tumor xenograft
growth
In contrast to U87wtEGFR tumors, linear tumor growth curves
fit only the control, radiation-only, and cetuximab-only groups
containing EGFRvIII xenografts. The TMZ-only and all combi-
nation groups showed a markedly non-linear tumor growth, with
tumors being stable initially and then shrinking at varying rates
(Figure 2B; Table 2). The control group had an estimated average
daily tumor growth rate of 19.3%, corresponding to an estimated
average tumor doubling time of about 3.9 days (Table 2). Com-
pared to the untreated controls, radiation alone showed significant
slowing of tumor growth (8.2%, p= 0.001), but cetuximab alone
was only marginally better (13.3%, p= 0.074). For the remaining
groups, tumor growth rate was not constant over the 4–5 weeks of
follow-up (non-linear tumor growth pattern). (Estimated growth
rates at days 0, 7, 14, and 21 are shown in Table 2). The combina-
tion of radiation, TMZ, and cetuximab had the most pronounced
curvature, reflecting an increasingly faster rate of tumor shrink-
age toward the end of the follow-up, compared to the other
groups. A total of 18 tumors across all groups regressed com-
pletely. This number was considerably higher than the number
of regressors (five regressors in the three-way combination group)
seen in U87wtEGFR tumors. In summary, treatment effects for the
EGFRvIII tumors were more dramatic, with tumor shrinkage seen
in the three-way combination and all three two-way combination
treatment groups as well as the TMZ-only group.
IN VITRO STUDIES OF U87EGFR AND U87EGFRvIII-EXPRESSING CELLS
In order to understand the greater response of the U87EGFRvIII
tumors to treatments, especially with TMZ and TMZ in combi-
nation therapy, we examined U87wtEGFR and U87EGFRvIII cells
with regard to: (1) MGMT status; (2) DNA damage and repair
ability; (3) cell viability and (4) clonogenic survival.
MGMT status
U87EGFR and U87EGFRvIII transfectants were similar in that
they lacked expression of the DNA-repair protein, MGMT,
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FIGURE 2 | Estimated geometric mean tumor volume over time after
single and combined treatments with RT, cetuximab, orTMZ. (A)
U87wtEGFR; (B) U87EGFRvIII. Mixed-effects linear regression, as described
in Section “Materials and Methods,” was used to model tumor volume as a
function of time and treatment. Each treatment group consisted of 10–15
animals.
which prevents cross-linking of double-stranded DNA by TMZ
(Figure 1B).
Rad51 foci assays
Previous studies have linked TMZ sensitivity to efficacy of homol-
ogous recombination repair (HRR) of DNA damage (Tsaryk et al.,
2006). Since Rad51 is a key player in the HRR pathway, studies
quantifying Rad51 foci formation and disappearance in the nuclei
of EGFR and EGFRvIII cells were made following TMZ and/or
RT treatment. Rad51 foci were detectable in nuclei 30 min, 4 and
24 h following treatment with 4 Gy and/or TMZ in both trans-
fectants (Figure 3A). For U87wtEGFR, the number of positive
cells exhibiting nuclear Rad51 foci following treatment with TMZ
alone was highest 4 h after treatment, exhibiting a 1.9-fold increase
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over that of control. After 24 h, the number decreased to 1.5-fold.
After treatment with TMZ and radiation, the number of nuclear
Rad51 foci was highest 30 min after treatment, resulting in a 2.5-
fold increase over control. After 24 h, the number decreased to
1.9-fold. (p< 0.05 for all comparisons with control).
For U87EGFRvIII, the number of positive cells exhibiting
nuclear Rad51 foci following treatment with TMZ was highest
at 24 h, exhibiting a 2.4-fold increase over that of control. This
change was significantly higher than the 1.5-fold-change observed
for EGFR tranfectants following 24 h of treatment (p= 0.003).
Treatment with TMZ combined with radiation resulted in a max-
imal increase of Rad51 foci at 24 h [3.5-fold over that of control
Table 1 | Estimates of the geometric mean tumor volume (in mm3)
over time, as well as the tumor growth rate and doubling time, by
treatment group, for the wtEGFR U87 glioblastoma cell line.
Time (days) %∆ T2x
0 7 14 21 28 35
CTR 66 303 1402 * * * 24.4 3.2
RT 69 173 433 1084 * * 14.0 5.3
TMZ 74 235 741 * * * 17.9 4.2
Cetuximab 58 190 615 1996 * * 18.3 4.1
RT+TMZ 79 187 442 1046 * * 13.1 5.6
RT+ cetuximab 71 151 325 697 1494 * 11.5 6.4
TMZ+ cetuximab 82 140 239 408 698 1193 8.0 9.0
RT+TMZ+ cetuximab 61 63 47 25 10 3 n/a n/a
*Predicted geometric mean greater than 2,000mm3 (beyond data range).
%∆, estimated average rate of increase of tumor volume (% daily change).
n/a, not applicable (tumor shrinkage over time,with estimated average daily tumor
size decrease of 1.9% on day 7, 6.3% on day 14, 10.5% on day 21, and 14.5% on
day 28).
T2x, estimated average doubling time of tumor volume (in days).
(Figure 3A)]. Rad51 foci were down to control levels (data not
shown) 48 h after treatment.
These data indicate a slower rate of nuclear Rad51 foci accumu-
lation and slower rate of disappearance for the EGFRvIII transfec-
tants compared with wtEGFR transfectants. Immunofluorescent
staining revealed that Rad51 was more cytoplasmic than nuclear
in U87EGFRvIII cells, compared to U87wtEGFRcells following 4 h
treatment with TMZ (Figures 3B,C), indicating a slower transloca-
tion of Rad51 into nuclei. Since it was previously shown that Akt1
can inhibit HRR by inducing cytoplasmic retention of Rad51 (Plo
et al., 2008), additional experiments were performed with a pan
Akt inhibitor, BAY1001931 during treatment with TMZ and/or RT
to see if Rad51 translocation into the nucleus was affected differ-
ently in U87EGFRvIII vs. U87wtEGFR cells. Figure 4A shows a
higher fold accumulation of nuclear Rad51 relative to control in
the EGFRvIII nuclei compared to wtEGFR nuclei following Akt
inhibitor treatment; Figure 4B shows immunofluorescent images
of increased Rad51 nuclear staining compared to control following
Akt inhibitor treatment in the EGFRvIII transfected cells whereas
Rad51 nuclear staining does not change following Akt inhibitor
treatment in the wtEGFR-transfected cells. These data suggest
that HRR after TMZ treatment in EGFRvIII-transfected cells is
retarded because of Akt-activated sequestration of Rad51 in the
cytoplasm.
Effect of TMZ and TMZ in combination with RAD51 inhibitor (B02) on
cell viability in U87EGFR vs. U87EGFRvIII cells
In order to confirm the increased sensitivity of U87EGFRvIII
tumors to TMZ seen in vivo (Figures 2A,B), cell viability assays
were performed for U87EGFR and U87EGFRvIII cells in the
presence of TMZ (500µM; Figure 5). It can be seen that
U87EGFRvIII cells were significantly more sensitive to TMZ
(500µM; p< 0.01 for all concentrations). In addition, Rad51 inhi-
bition by B02 increased sensitivity in U87EGFRvIII cells over that
of wtEGFR cells (p< 0.05).
Table 2 | Estimates of the geometric mean tumor volume (in mm3) over time and tumor growth rate, by treatment group, for the EGFRvIII U87
glioblastoma cell line.
Tumor volume %∆
Time (days) Time (days)
0 7 14 21 28 35 0 7 14 21
CTR 70 241 827 * * * 19.3
RT 88 153 265 460 797 1383 8.2
TMZ 112 130 112 72 34 12 4.4 0.0 −4.2 −8.2
Cetuximab 86 206 493 1182 * * 13.3
RT+TMZ 94 90 75 54 34 18 0.4 −1.6 −3.6 −5.5
RT+ cetuximab 75 57 30 11 ** ** −1.2 −6.3 −11.0 −15.6
TMZ+ cetuximab 88 78 51 25 ** ** 0.4 −3.8 −7.8 −11.6
RT+TMZ+ cetuximab 55 54 24 ** ** ** 5.9 −5.7 −16.0 −25.1
*Predicted geometric mean greater than 2,000mm3 (beyond data range).
**Predicted geometric mean less than 10mm3 (tumor regression).
%∆, estimated average rate of increase or decrease of tumor volume (% daily change).
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FIGURE 3 | Effect ofTMZ and/or RT on Rad51 foci formation in the
nuclei of U87wtEGFR and U87EGFRvIII cells. Fold-change in nuclear
Rad51 foci relative to control levels after treatments with TMZ (20µM)
and/or RT (4 Gy). The mean±SEM from three independent
experiments were obtained with three replicates per experiment. (A)
Fold-change in nuclear Rad51 foci relative to control levels following
TMZ and/or RT treatment. (B,C) Micrographs showing DAPI staining of
nuclei (left panel) and Rad51 staining (right panel) 4 h following TMZ
treatment of U87wtEGFR and U87EGFRvIII respectively. Magnification:
400×.
CLONOGENIC CELL SURVIVAL AFTER RADIATION, TMZ, AND/OR
CETUXIMAB
Figures 6A,B indicate the toxicities for cetuximab, TMZ, and
cetuximab and TMZ in combination normalized to the plating
efficiencies for wtEGFR (P.E.= 0.43) and EGFRvIII (P.E.= 0.36).
Figures 6C,D demonstrate that TMZ alone and in combina-
tion with cetuximab significantly radiosensitized both transfec-
tants (p< 0.001 for TMZ/cetuximab vs. control). There was
no significant difference in radiosensitization by TMZ between
the transfectants under the conditions of this assay. Cetuximab
enhanced radiosensitization in EGFRvIII transfectants (p< 0.002
vs. control) but not in wtEGFR.
DISCUSSION
This study demonstrated that U87EGFRvIII-expressing tumors
are more sensitive than U87wtEGFR-expressing tumors to
treatment with TMZ alone and TMZ in combination with cetux-
imab and/or RT. Factors that may contribute to TMZ sensitivity
include: a high proliferation rate (Roos et al., 2009); methyla-
tion status of the repair enzyme, MGMT (Esteller et al., 2000);
efficacy of DNA repair (Kil et al., 2008). With regard to prolifera-
tion rate, the doubling time of U87EGFRvIII tumors was actually
slower than that of U87wtEGFR tumors in this study, therefore, the
increased sensitivity to TMZ observed in these tumors compared
to U87wtEGFR tumors could not be explained by proliferation rate
differences. With regard to methylation status, U87 GBM cells are
known to have hypermethylated MGMT promoters (Hermes et al.,
2008) and therefore lack detectable MGMT expression on west-
ern blots. Likewise, both U87wtEGFR and U87EGFRvIII tumors
derived from the parent U87 cells lacked detectable MGMT expres-
sion (data not shown). Consequently, MGMT status could not
explain the high sensitivity to TMZ that was seen in U87EGFRvIII
tumors.
With regard to efficacy of DNA repair, it has been reported that
TMZ can inhibit DNA DSB repair. However, it is not known if one
or both of the two key complementary DNA DSB repair pathways,
non-homologous end-joining (NHEJ) or HRR are involved in
this inhibition. EGFRvIII-expressing cells were shown to acceler-
ate repair of radiation-induced DNA DSBs through upregulation
of DNA-PKc, the catalytic subunit of DNA-PK, a key enzyme in
the NHEJ pathway (Mukherjee et al., 2009). Although, NHEJ is
a very active repair pathway in EGFRvIII following radiation, it
is not apparently related to TMZ sensitivity (Roos et al., 2009).
There is evidence, however, that HRR may play a role in TMZ
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FIGURE 4 | Effect of Akt inhibitor (BAY 1001931) on nuclear
accumulation of Rad51 foci 24h followingTMZ treatment in
U87wtEGFR and U87EGFRvIII cells. (A) Fold-change in nuclear
Rad51 foci relative to control levels. (B) Micrographs showing DAPI
staining of nuclei and Rad51 staining 24 h following TMZ treatment
(20µM) with and without Akt inhibitor [BAY1001931 (500 nM) of
U87EGFRvIII (a) and U87wtEGFR (b) respectively. Magnification:
400×.
FIGURE 5 | Effect ofTMZ and BO2 on cell viability in U87EGFR vs.
U87EGFRvIII cells. Cell viability was measured by an MTS assay (Promega,
Madison, WI, USA) as described in Section “Materials and Methods,” with
four replicates per treatment. Experiments were repeated in triplicate.
sensitivity (Tsaryk et al., 2006). A deficiency in HRR signal-
ing via XRCC2 or other repair enzymes involved in HRR (i.e.,
Rad51, Rad52, Brca2) might explain increased sensitization to
TMZ in EGFRvIII-expressing tumors, especially in light of stud-
ies with XRCC2- and Brca2-deficient cells (Tsaryk et al., 2006;
Roos et al., 2009) showing increased sensitization to TMZ. We
examined the formation of Rad51 foci to see if HRR is defective
in EGFRvIII-expressing cells. We found a slower rate of accu-
mulation and slower rate of disappearance of nuclear Rad51
foci in U87EGFRvIII vs. U87wt/EGFR transfectants. In addi-
tion, Rad51 staining was largely perinuclear or cytoplasmic in
U87EGFRvIII cells compared to U87wtEGFR cells 4 h follow-
ing TMZ treatment. Previous studies indicated that EGFRvIII-
expressing cells constitutively activate phosphatidylinositol 3-
Kinase (PI3-K) and Akt1 (Moscatello et al., 1998), and that Akt1
can inhibit HRR by inducing cytoplasmic retention of Rad51
(Plo et al., 2008). Our current study found that inhibition of
Akt can increase the rate of nuclear foci accumulation of Rad51
in the EGFRvIII cells compared to EGFR cells and that Rad51
inhibition can heighten sensitivity of EGFRvIII to TMZ. It is
therefore suggested that defective HRR may contribute to the
heightened sensitivity of EGFRvIII tumors to TMZ observed in
this study.
This study also demonstrated that U87EGFRvIII tumor growth
was very sensitive to dual treatment with cetuximab plus radi-
ation, causing tumor regressions. Previous investigators deter-
mined that gefitinib, a receptor tyrosine kinase inhibitor of EGFR
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FIGURE 6 | Effect ofTMZ and/or cetuximab on clonogenic cell
survival and radiosensitivity in U87EGFR vs. U87EGFRvIII cells.
Cetuximab and/or TMZ were applied to exponentially growing cells 24 h
prior to irradiation. (A,B) effect of TMZ and/or cetuximab on clonogenic
cell survival; (C,D) relative radiosensitivities of U87wtEGFR and
U87EGFRvIII in the presence of TMZ and/or cetuximab. The
mean±SEM from at least three independent experiments were
obtained.
can reduce radioresistance in EGFRvIII-expressing mouse astro-
cytes through attenuation of DNA dsb repair (Mukherjee et al.,
2009). The present study does indicate increased radiosensitiza-
tion in the presence of cetuximab in U87EGFRvIII compared
to U87EGFR in vivo and in vitro. It is concluded that blocking
EGFR/EGFRvIII by cetuximab alone will most likely not translate
into a clinical benefit, whereas incorporation of EGFR inhibitor
signaling into a combined modality approach will more likely
lead to improvement of GBM tumor control. Additionally, the
difference in sensitivity between EGFR-expressing and EGFRvIII-
expressing tumors to triple modality treatment observed in this
study appears to be largely the result of increased TMZ sensiti-
zation as well as increased sensitivity to cetuximab and radiation
in EGFRvIII tumors and may contribute to individual variation in
response to treatment, depending on the level of EGFRvIII expres-
sion. Of direct relevance to the present study are the recent clinical
findings that patients whose GBM tumors express EGFRvIII have
prolonged survival after radiation and chemotherapy with TMZ
(Montano et al., 2011). The same study demonstrated in vitro that
GBM cells lacking EGFRvIII are more resistant to TMZ. Our cur-
rent study may help in future tailoring of GBM therapy to subsets
of patients expressing more or less of the EGFR mutant.
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